Role of ProExC: A novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens

International Journal of Gynecological Pathology

Volumn 29, Issue 1, 2010, Pages 79-87

  Sanati, Souzan ^a   Huettner, Phyllis ^a   Ylagan, Lourdes R ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

ASC; Atypical squamous cells of undetermined significance; H; Minichromosome maintenance; ProExC; Topoisomerase II alpha proteins

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); MINICHROMOSOME MAINTENANCE PROTEIN 2; PROEXC; PROEXC ANTIBODY; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL METAPLASIA; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 76149114613     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181ae81a0     Document Type: Article

References (41)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Williams GH, Romanowski P, Morris L, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998; 95:14932-14937
3. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 2005;4(suppl):17-23.
4. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 2003;63:1927-1935
5. Larsen NS. Invasive cervical cancer rising in young white females. J Natl Cancer Inst 1994;86:6-7.
6. Tachibana KK, Gonzalez MA, Coleman N. Cell-cycledependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005;205:123-129
7. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505
8. Clarke B, Chetty R. Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2001;82:238-246
9. The Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
10. Dellas A, Schultheiss E, Oberholzer M, et al. Analysis of proliferative activity using Ki-67 on cervical precancerous lesions and the relationship to p53 expression. Anticancer Res 1996;16:3403-3407 (Pubitemid 27084989)
11. Dunton CJ, van Hoeven KH, Kovatich AJ, et al. Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia. Gynecol Oncol 1997;64:451-455
12. Gibbons D, Fogt F, Kasznica J, et al. Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. Mod Pathol 1997;10:409-413
13. Garzetti GG, Ciavattini A, Lucarini G, et al. p53 Immunostaining and HPV DNA detection by PCR in cervical intraepithelial neoplasia: clinical implications of a combinated evaluation. Anticancer Res 1997;17:555-560
14. Dellas A, Schultheiss E, Almendral AC, et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 1997;74:421-425
15. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-284
16. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004;35:689-696
17. Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004;4:58.
18. Murphy N, Heffron CC, King B, et al. p16INK4A Positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch 2004;445: 610-615
19. Dray M, Russell P, Dalrymple C, et al. p16(INK4a) As a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 2005;37: 112-124
20. Kalof AN, Cooper K. p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 2006;13:190-194
21. Pavlakis K, Messini I, Athanassiadou S, et al. Endocervical glandular lesions: a diagnostic approach combining a semiquantitative scoring method to the expression of CEA, MIB-1 and p16. Gynecol Oncol 2006;103:971-976
22. Mulvany NJ, Allen DG, Wilson SM. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 2008;40:335-344
23. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210-220
24. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005;331:269-291
25. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-323
26. Shi J, Liu H, Wilkerson M, et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase II alpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol 2007;38: 1335-1344
27. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
28. Mc Leod HL, Douglas F, Oates M, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 1994;59:607-611
29. Davidson B, Goldberg I, Lerner-Geva L, et al. Expression of topoisomerase II and Ki-67 in cervical carcinoma-clinicopathological study using immunohistochemistry. APMIS 2000;108:209-215
30. Branca M, Giori C, Ciotti M, et al, HPV-Pathogen Study Group. Over-expression of topoisomerase II alpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol 2006;25:383-392 (Pubitemid 44651772)
31. Ha SA, Shin SM, Namkoong H, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res 2004;10:8386-8395
32. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-2132
33. Gonzalez MA, Tachibana KK, Laskey RA, et al. Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 2005;5:135-141
34. Van de Putte G, Hristensen GB, Lie K, et al. Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol 2004;92:40-46 (Pubitemid 38147369)
35. Ishimi Y, Okayasu I, Kato C, et al. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur J Biochem 2003;270:1089-1101
36. Kelly D, Kincaid E, Fansler Z, et al. Detection of cervical highgrade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer 2006;108:494-500.
37. Shroyer KR, Homer P, Heinz D, et al. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006;108:324-330
38. Solomon D, Nayar R. The Bethesda System for Reporting Cervical Cytology. New York: Springer-Verlag, Inc.; 2004.
39. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer 2006;108:298-305.
40. Saqi A, Gupta PK, Erroll M, et al. High-risk human papillomavirus DNA testing: a marker of atypical glandular cells. Diagn Cytopathol 2006;34:235-239
41. Ozkan F, Ramzy I, Mody DR. Glandular lesions of the cervix on thin-layer Pap tests. Validity of cytologic criteria used in identifying significant lesions. Acta Cytol 2004;48:372-379